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ARTICLE OPEN
Relative contributions of adipose-resident CD146+ pericytes
and CD34+ adventitial progenitor cells in bone tissue
engineering
Yiyun Wang1, Jiajia Xu 1, Leslie Chang1, Carolyn A. Meyers1, Lei Zhang1, Kristen Broderick2, Min Lee3, Bruno Peault4,5 and Aaron W.
James1,4
Pericytes and other perivascular stem/stromal cells are of growing interest in the ﬁeld of tissue engineering. A portion of
perivascular cells are well recognized to have MSC (mesenchymal stem cell) characteristics, including multipotentiality, self-renewal,
immunoregulatory functions, and diverse roles in tissue repair. Here, we investigate the differential but overlapping roles of two
perivascular cell subsets in paracrine induction of bone repair. CD146+CD34−CD31−CD45−pericytes and
CD34+CD146−CD31−CD45−adventitial cells were derived from human adipose tissue and applied alone or in combination to
calvarial bone defects in mice. In vitro, osteogenic differentiation and tubulogenesis assays were performed using either
ﬂuorescence activated cell sorting-derived CD146+ pericytes or CD34+ adventitial cells. Results showed that CD146+ pericytes
induced increased cord formation in vitro and angiogenesis in vivo in comparison with patient-matched CD34+ adventitial cells. In
contrast, CD34+ adventitial cells demonstrated heightened paracrine-induced osteogenesis in vitro. When applied in a critical-size
calvarial defect model in NOD/SCID mice, the combination treatment of CD146+ pericytes with CD34+ adventitial cells led to
greater re-ossiﬁcation than either cell type alone. In summary, adipose-derived CD146+ pericytes and CD34+ adventitial cells
display functionally distinct yet overlapping and complementary roles in bone defect repair. Consequently, CD146+ pericytes and
CD34+ adventitial cells may demonstrate synergistic bone healing when applied as a combination cellular therapy.
npj Regenerative Medicine             (2019) 4:1 ; https://doi.org/10.1038/s41536-018-0063-2
INTRODUCTION
The vascular wall within adipose tissue (AT) is a source of stromal
progenitor cells, often referred to as perivascular stem/stromal
cells (PSC), vascular wall-resident mesenchymal stem cell (MSC), or
tissue-speciﬁc MSC. Perivascular cells have long been supposed to
be the cell type culpable for pathologic vascular ossiﬁcation.1,2
Perivascular AT is an appealing source of stromal cells for skeletal
regenerative medicine, as it is an easily accessible and dispensable
cell source.3–5 The unpuriﬁed stromal vascular fraction (SVF) of AT
has been previously used for bone repair, but formed bone tissue
unreliably6 or with a low efﬁcacy.7 Variability in cell subset
frequency within different preparations of SVF may represent one
factor predisposing to unreliable tissue formation.
Cells within perivascular AT are well recognized to have MSC
characteristics, including multipotentiality, self-renewal, immunor-
egulatory functions, and diverse roles in tissue repair. The in situ
identiﬁcation of pericytes as a tissue-resident MSC population was
ﬁrst reported in 2008,8 although the probable progenitor cell
identity of pericytes had been shown as early as 1999.9–11 The
identiﬁcation of CD34+ progenitor cells within the tunica
adventitia was described as early as 2007,12,13 and their tissue-
resident MSC identity was most clearly documented in 2012.14
Both AT-derived CD146+ pericytes8 and CD34+ adventitial cells14
are multipotential when cultured under appropriate conditions
(observed to form osteoblasts, chondroblasts, and adipocytes),
and give rise to bone cells when implanted within15 or outside a
bone microenvironment.16 Because of the overlapping features of
CD146+ pericytes and CD34+ adventitial cells, they have most
commonly been combined for tissue engineering applications
under the umbrella term “perivascular stem/stromal cells, PSC”
(see ref. 17 for a review).
Despite their shared perivascular residence, studies suggest that
AT-derived CD146+ pericytes and CD34+ adventitial cells have
clear differences. In earlier descriptions by Corselli et al., CD34+
adventitial cells can adopt a pericyte-like immunophenotype
under appropriate culture conditions.14 This suggested a ﬂuidity
between perivascular cell types, but also that adventitial cells
represent a more “stem” or progenitor cell type. Recent single-cell
transcriptional analysis supports this concept of a functional and
developmental hierarchy within the perivascular niche of human
AT.18 Here, 178 individual perivascular cells from a single donor’s
AT were examined on a Fluidigm platform. Among 429 gene
transcripts examined, a clear separation between CD146+
pericytes and CD34+ adventitial cells was observed by hierarchical
clustering and principal component analysis.18 Adventitial cells
preferentially expressed a few genes of pluripotency or stemness
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(e.g., NANOG, CMYC, KLF2), growth factor receptors characteristic
of progenitor cells (e.g., FGFR2, PDGFRA, TGFBR1A), as well as the
osteogenic transcription factor RUNX2. In contrast, pericytes
preferentially expressed genes involved in angiogenesis and
vascular smooth muscle cell function (e.g., ACTA2, ANGPT2). In
aggregate, these gene signatures suggested functionally relevant
differences between CD146+ pericytes and CD34+ adventitial cells
when placed in a bone defect microenvironment.
RESULTS
Combinatorial efﬁcacy with CD146+ pericytes and CD34+
adventitial cells in calvarial bone repair
Microvascular pericytes (CD146+CD34−CD31−CD45−) and adven-
titial progenitor cells (CD34+CD146−CD31−CD45−) were isolated
from de-identiﬁed human white AT liposuction specimens based
on previously established protocols.19 Fluorescence activated cell
sorting (FACS)-based isolation of distinct perivascular cell popula-
tions is shown in Supplementary Figure 2. In brief, after removal of
DAPI+ non-viable cells, CD31+ endothelium and CD45+ inﬂam-
matory cells, CD146+CD34− pericytes represented 1.81% of total
mononuclear cells, whereas CD34+CD146−adventitial cells repre-
sented 31.26% of total mononuclear cells. To discern the relative
functions of each perivascular cell population, uncultured CD146+
pericytes and CD34+ adventitial cells were applied in equal
numbers, alone or in combination, to non-healing calvarial bone
defects in mice (see Supplementary Figure 1 and Supplementary
Table 2 for a breakdown of cell numbers and treatment
conditions). All cells were obtained from the same patient’s
adipose sample. An osteoinductive hydroxyapatite-coated poly
(lactic-co-glycolic acid) (PLGA) scaffold was used for cell delivery,
as used in prior reports,20 and short-term incubation was
performed prior to in vivo application. LIVE/DEAD cell viability
staining was performed on selected scaffolds after cell seeding,
and in all cases showed overall an even distribution of viable cells
throughout the scaffold and negligible cell death across treatment
groups (Supplementary Figure 3). Similar cell engraftment, similar
distribution throughout the defect site, similar basal proliferative
potential (Ki67 staining), and similarly infrequent apoptosis
(terminal deoxynucleotidyl transferase (TdT) dUTP nick-end
labeling; TUNEL staining) was observed among either CD146+
pericytes and CD34+ adventitial cells when examined at an
early timepoint postoperative (3d postoperative, Supplementary
Figure 4).
Microcomputed tomography (microCT) imaging and analysis
was performed at 8 weeks post implantation (Fig. 1). Images are
shown in a 3D coronal cross-section (Fig. 1a), with quantitative
analysis below (Fig. 1b–d). On coronal cross sections, the original
defect edges are indicated by black arrowheads. As expected of a
critical-size defect, the “no scaffold” group without treatment
showed an essential absence of bone healing. Sparse radiodensity
was observed with the “scaffold alone” without cell treatment.
Patchy re-ossiﬁcation was seen with either CD146+ pericytes or
CD34+ adventitial cells alone. Interestingly, frank defect site re-
ossiﬁcation was only observed within the combination therapy of
“pericytes+ adventitial cells“. These ﬁndings were examined
Fig. 1 Microcomputed tomographic (microCT) imaging and analysis of calvarial defect healing with CD146+ pericytes or CD34+ adventitial
cells, alone or in combination. a 3D coronal section reconstructions of calvarial defect site among “no scaffold” control, “scaffold alone“
control, or three different cell treatment groups. “Pericyte” group consisted of 2.5 × 105 CD146+CD34−CD45−CD31− pericytes. “Adventitial”
group consisted of 2.5 × 105 CD34+CD146−CD45−CD31− adventitial cells. “Pericyte+ Adventitial” group consisted of a 50%/50% split
between each cell type (1.25 × 105 adventitial cells and 1.25 × 105 pericytes). b–d MicroCT quantiﬁcation of bone repair in calvarial defects
within each treatment group, 8 weeks postoperative. b Bone volume, c bone volume/ttissue volume, and d Bone fractional area. *P < 0.05, **P
< 0.01 in comparison with “no scaffold” group. N= 46 bone defects per treatment group
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quantitatively, by analysis of bone volume (Fig. 1b, BV), fractional
bone volume (Fig. 1c, bone volume/issue volume, BV/TV), and
bone fractional area (Fig. 1d, BFA). In each case, the combination
of equal numbers of pericytes+ adventitial cells outpaced all
other treatment groups in terms of indices of bone repair.
Histologic appearance of CD146+ pericyte- and CD34+ adventitial
cell-treated calvarial bone defects
The histologic appearance of calvarial defect sites was next
examined (Fig. 2). The “no scaffold” group had minimal tissue for
examination and is not included in this analysis. Representative
images from haemotoxylin and eosin (H&E) or Masson’s
Trichrome-stained sections are shown (Fig. 2a). Sections of the
“scaffold alone” treatment group showed scattered ﬁbroblastic
cells embedded in a ﬁbrous stroma (Fig. 2a, far left). Sections of
defect sites treated with CD146+ pericytes were observed to have
a qualitative increase in small blood vessel density most easily
observed on Trichrome-stained sections (Fig. 2a, middle left).
Scattered immature woven bone formation was also seen (not
shown). Sections of defect sites treated with CD34+ adventitial
cells showed more conspicuous dense ﬁbrous tissue along with a
slight increase in defect site vascularization (Fig. 2a, middle right).
Conspicuous bone formation was only observed among the
combination cellular therapy “pericytes+ adventitial” cells (Fig. 2a,
far right). These observed differences were next quantiﬁed by
histomorphometric analysis of serial cross sections (Fig. 2b–d). A
trend toward increase defect site vascularization was observed
across all cell therapies, as assessed by both blood vessel density
and vessel area (Fig. 2b, c). These differences were most robust
and achieved statistical signiﬁcance among the “pericyte only” cell
treatment group, which demonstrated a 117% increase in vessel
density (Fig. 2b, blue bars) and 287% increase in normalized vessel
area (Fig. 2c, blue bars). Quantiﬁcation of bone matrix was next
performed. In line with our histologic observations, a signiﬁcant
increase in bone area was only appreciated with the combination
therapy “pericytes+ adventitial” cells (Fig. 2d, green bars). Finally,
we assessed for long term persistence of human perivascular cells
within the defect site. Consistent with prior reports suggesting a
primary paracrine mechanism of action for human PSC,21
immunohistochemistry against human nuclear antigen showed
no signiﬁcant persistence of human cells at the eight week study
endpoint (Supplementary Figure 5).
Vascular tubulogenesis stimulated by CD146+ pericytes or CD34+
adventitial cells
In order to gain a more isolated understanding for the functional
differences between CD146+ pericytes and CD34+ adventitial
cells, co-culture experiments were ﬁrst performed with human
umbilical vein endothelial cells (HUVECs) (Fig. 3). CD146+ pericytes
or CD34+ adventitial cells were labeled with PKH26 dye and
Fig. 2 Histologic analysis of calvarial defect healing with CD146+ pericytes or CD34+ adventitial cells, alone or in combination. a
Representative hematoxylin/eosin and Masson’s trichrome images of the defect site. Scale bar= 50 μm. Representative images are shown of
the “scaffold alone” control, or three different cell treatment groups. “Pericyte” group consisted of 2.5 × 105 CD146+CD34−CD45−CD31−per-
icytes. “Adventitial” group consisted of 2.5105 CD34+CD146−CD45−CD31−adventitial cells. “Pericyte+ Adventitial” group consisted of a 50%/
50% split between each cell type (1.25 × 105 adventitial cells and 1.25 × 105 pericytes). b, c Vascular histomorphometry of the defect site,
including b blood vessel density, and c normalized vessel area per ﬁeld. d Bone histomorphometry of the defect site, including bone area per
ﬁeld. *P < 0.05 in comparison with “Scaffold alone” group. N= 4−6 bone defects per treatment group. N= 6 images analyzed per sample
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cultured with HUVEC at equal ratios. Cord formation was assessed
at 1 and 4 h post seeding (Fig. 3a–c). Results showed that CD146+
pericytes induced a signiﬁcant increase in cord formation at both
1 and 4 h, as assessed by random imaging ﬁelds (Fig. 3a).
Quantiﬁcation of cord length, branchpoints, and mesh number
was assessed per ﬁeld of view (FV) (Fig. 3b, c). CD146+ pericytes
induced an increase in all metrics across all timepoints, although
not all datapoints reached statistical signiﬁcance (blue versus gray
bars, Fig. 3b, c). In contrast, no statistically signiﬁcant difference in
cord formation was appreciated with CD34+ adventitial cell co-
Fig. 3 Differential effects on HUVEC cord formation by CD146+ pericytes or CD34+ adventitial cells. a, b HUVECs were seeded in culture alone,
or with either CD146+ pericytes or CD34+ adventitial cells. In all cases, pericytes or adventitial cells were labeled with PKH26+ red ﬂuorescent
lipophilic dye. Cord formation was assessed at 1 and 4 h post seeding. a Representative images at × 10magniﬁcation. Left: HUVECs cultured
alone (HUVEC alone). Middle: HUVECs and CD146+CD34-CD45−CD31− pericyte co-culture (HUVEC+ Pericyte). Right: HUVECs and
CD34+CD146−CD45−CD31−adventitial cells co-culture (HUVEC+ Adventitial). b, c Quantiﬁcation of length, branchpoints, and meshes per
ﬁeld view (FV) of a at b 1 h and c 4 h. *P < 0.05, **P < 0.01 in comparison with HUVEC alone group. d Relative attachment of CD146+ pericytes
or CD34+ adventitial cells on pre-formed HUVEC cords. PKH26+ red ﬂuorescent-labeled pericytes or adventitial cells were seeded on newly
formed HUVEC network. Images shown at 1 and 4 h after perivascular cell seeding. Both pericytes and adventitial cells showed signiﬁcant
tropism for newly formed HUVEC network. e Quantiﬁcation of attachment of cells on the networks, represented as a percentage of the
PKH26+ cells in contact with the network per total PKH26+ cells per ﬁeld. f Quantiﬁcation of attachment of cells on the branchpoints,
represented as a percentage of PKH26+ cells in contact with the branchpoints per total PKH26+ cells per ﬁeld. *P < 0.05. N= 3 wells and three
images per group. g Angiogenic protein array demonstrating secreted proteins from either CD146+ pericytes (above) or CD34+ adventitial
cells (below) after 24 h in culture. Captured antibodies to speciﬁc target proteins were spotted in duplicate. h Secretion level of each
angiogenesis-related protein measured as pixel density of the pair of duplicate spots and normalized to negative control spots
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culture in comparison with HUVECs alone (red versus gray bars,
Fig. 3b, c).
Next, we inquired as to whether CD146+ pericytes and CD34+
adventitial cells had differential tropism to HUVEC networks
in vitro (Fig. 3d–f). Here, CD146+ pericytes or CD34+ adventitial
cells were seeded on pre-formed HUVEC networks. The frequency
of attachment of PKH26+ perivascular cells to cords (Fig. 3e) or
cord branchpoints (Fig. 3f) was assessed at early timepoints post
seeding. Qualitatively, both pericytes and adventitial cells showed
prominent tropism to the outside aspects of cords (Fig. 3d). The
percentage attachment was assessed at 1 and 4 h post seeding
(Fig. 3e, f). The majority of both perivascular cells showed cord
attachment, which signiﬁcantly increased over time (Fig. 3e,
80–85% attachment at 1 h, 87–91% attachment at 4 h). A trend
toward increased CD146+ pericyte attachment was noted,
although this did not reach statistical signiﬁcance at either
timepoint. CD146+ pericytes were also noted to preferentially
attach to the branchpoints of networks (see especially 4 h images
post seeding). These ﬁndings were quantiﬁed, demonstrating a
signiﬁcant preference for CD146+ pericytes rather than CD34+
adventitial cells to attach to branchpoints (Fig. 3f, 70–74% pericyte
attachment to branchpoints, in comparison with 50–65% adven-
titial cell attachment to branchpoints). Thus, in similarity to our
in vivo ﬁndings, CD146+ pericytes appear to preferentially induce
cord formation in vitro. In addition, although tropism toward
vascular cords is a conserved feature of both perivascular cell
populations, CD146+ pericytes appear to preferentially be found
at sites of cord branching.
In order to begin to understand the differences in paracrine-
induced cord formation between CD146+ pericytes and CD34+
adventitial cells, the angiogenic secretome of patient-identical
CD146+ pericytes vs CD34+ adventitial cells was next examined
(Fig. 3g, h). Of 55 angiogenesis-related proteins, 21 showed
detectable expression in the supernatant of either pericytes or
adventitial cells (Fig. 3g). Increased pericyte secretion of ﬁve
proteins were observed, including MCP1 (C-C motif chemokine
ligand 2), IGFBP1 (Insulin like growth factor binding protein 1),
IGFBP2 (Insulin-like growth factor binding protein 1), ANGPT1
(Angiopoietin 1), and uPA (Plasminogen activator, urokinase) (Fig.
3h). Conversely, insulin-like growth factor binding protein 3 and
Pentraxin 3 showed higher secretion among adventitial cells.
Interestingly, no difference in vascular endothelial growth factor
was detected between CD146+ pericytes with CD34+ adventitial
cells.
Paracrine-induced osteogenesis by CD146+ pericytes or CD34+
adventitial cells
Our in vivo studies suggested potential combinatorial efﬁcacy
with CD146+ pericytes and CD34+ adventitial cells in bone-defect
healing. Beyond differences in stimulating vascularization, we next
sought to identify potential functional differences paracrine-
induced osteogenic differentiation (Fig. 4). Here, the potential
interaction between CD146+ pericytes and CD34+ adventitial cells
in speeding osteogenic differentiation of the counterpart cell type
was examined. CD146+ pericytes and CD34+ adventitial cells were
placed in non-contact co-culture, and osteogenic differentiation
was assessed under standard osteogenic differentiation condi-
tions. All cells were obtained from the same patient’s adipose
sample. Alizarin red staining of bone nodules was performed at
14 days after co-culture (Fig. 4a, b). Staining and photometric
quantiﬁcation showed that CD34+ adventitial cells induced a
robust increase in bone nodule formation among CD146+
pericytes. Conversely, CD146+ pericytes showed no signiﬁcant
effect on the osteogenic differentiation of their counterpart
CD34+ adventitial cells. These ﬁndings were recapitulated by gene
expression analysis by quantitative real-time polymerase chain
reaction (RT-PCR) (Fig. 4c, d). Little change in osteogenic gene
expression was observed among CD34+ adventitial cells with or
without paracrine stimulation by CD146+ pericytes. Instead,
changes in expression of angiogenesis-related factors were
identiﬁed, including MCP1, IGFBP1, and IGFBP2 (Fig. 4c). In contrast,
increased transcript abundance for the osteogenic transcription
factor RUNX2 (Runt-related transcription factor 2), enzyme ALP
(Alkaline Phosphatase), and matrix component COL1A1 (Type I
Collagen) were all found by paracrine stimulation of pericytes by
CD34+ adventitial cells (Fig. 4d). In contrast, adventitial cells
induced little change in angiogenesis-related gene expression
among CD146+ pericytes (Fig. 4d). In sum, these in vitro ﬁndings
suggest functional differences between perivascular subpopula-
tions. Paracrine-induced vasculogenesis is most appreciable
among CD146+ pericytes, whereas paracrine-induced osteogen-
esis is most associated with CD34+ adventitial cells.
DISCUSSION
Bone healing is associated with a conﬂuence of factors including
hemorrhage, local inﬂammation, progenitor cell migration, osteo-
genic and chondrogenic differentiation, and vascularization,
among other local and systemic factors. The present study
examined in detail the effects of perivascular progenitor cell
subpopulations on just two of these factors: osteogenic differ-
entiation and defect vascularization. In summary, we observed
that subpopulations of perivascular progenitor cell types demon-
strate distinct, overlapping, and potentially synergistic effects on
osteogenesis and vasculogenesis during bone repair. CD146+
pericytes have a more prominent pro-vasculogenic effect,
accompanied by increased elaboration of pro-angiogenic factors
such as ANGPT1 and uPA. Given the pericyte’s native residence
and known roles in regulating angiogenesis and revasculariza-
tion,22 these ﬁndings are to some extent intuitive. In contrast,
CD34+ adventitial cells have more prominent paracrine pro-
osteogenic effects. Given these distinct but overlapping roles in
bone repair, future use of a combination progenitor cell therapy
may be a more efﬁcacious approach than use of a single, more
homogenous cell preparation. Although equal numbers of
pericytes and adventitial cells have been mixed in the combina-
tion progenitor cell therapy experiments reported here, it will be
important to determine whether different ratios of these two cell
types can support even more dramatic osteogenesis. As well, our
observation that CD146+ pericytes induce heightened vascular-
ization suggests that this population may be most useful alone in
contexts of ischemic tissue repair. This concept is borne out by
prior studies, in which the promise of pericyte application in
cardiac ischemic repair has been well-demonstrated.22–25
Previous investigators have used cell separation techniques
including FACS to purify AT-derived cell populations for tissue
engineering purposes with some success.26–29 In fact, AT-derived
progenitor cells with a predilection for bone,26 adipose,27 or
cartilage formation27 have been deﬁned. However, existing
studies segregate AT progenitor cell therapies based on differ-
ential expression of cell surface signaling receptors, such as TGF-β
co-receptors26,27 or BMP receptors.28,29 This approach is funda-
mentally distinct from that presented here, and is an attempt to
retrospectively curate a mixed cell population rather than
prospectively isolate a cell type of interest. At present, it is not
clear how prior cell preparations overlap or correlate to either
CD146+ pericytes or CD34+ adventitial cells. Single-cell analysis of
AT-derived pericytes and adventitial cells did not ﬁnd these
previously used antigens as among those most differentially
expressed between perivascular cell types (including CD90, CD105,
BMPR1A, or BMPR1B).18
Several caveats exist toward the broader extrapolation of these
results. First, the bone model chosen is an intramembranous
model of bone repair and was chosen for its ease and
reproducibility. It remains to be seen if CD146+ pericytes and
Y. Wang et al.
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Fig. 4 Bidirectional paracrine effects of CD146+ pericytes and CD34+ adventitial cells during osteogenic differentiation in non-contact co-
culture in vitro. a Representative Alizarin Red S staining, whole well images after 14 days osteogenic differentiation. b Quantitative analysis of
Alizarin Red S staining shown using absorbance at 548 nm. c Quantitative RT-PCR analysis of osteogenic gene markers (RUNX2, ALP, COL1A1)
and angiogenesis-related gene markers (MCP1, IGFBP1, IGFBP2) among CD34+ adventitial cells with or without pericyte co-culture, day 7 of
osteogenic differentiation. d Quantitative RT-PCR analysis of osteogenic and angiogenic gene markers among CD146+ pericytes with or
without adventitial cell co-culture, day 7 of osteogenic differentiation. *P < 0.05. N= 3 wells per condition
Y. Wang et al.
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CD34+ adventitial cells have similar combinatorial efﬁcacy exists in
models of endochondral bone repair. Prior studies suggest that
CD146+ pericytes and CD34+ adventitial cells do indeed have
differential paracrine functions in chondrogenic differentiation
in vitro.30 Zhang et al. observed that CD34+ adventitial cells may
support chondrocyte proliferation, whereas CD146+ pericytes
stimulate glycosaminoglycan and cartilage-associated collagen
production.30 Second, it is clear from both histologic, structural,
and transcriptional standpoints that both perivascular populations
harbor intrinsic cellular diversity.31 Pericytes can be subdivided
across a spectrum of small vessel types including arterioles,
capillaries, and venules. In mice, functionally distinct pericyte
subtypes have been examined using nestin and NG2 transgenic
reporters.32–34 Similarly and in human tissue, Hardy et al. showed
that aldehyde dehydrogenase bright and dim subpopulations of
CD146+ AT-derived pericytes were transcriptionally distinct, and
this marker could be used to identify a more “primitive” pericyte
subpopulation.18 CD34+ adventitial cells can likewise be categor-
ized based on vessel type between arteries and veins. Gli1+
adventitial cells in mice have been shown to harbor progenitor
cell characteristics and give rise to the tunica media in physiologic
and pathologic conditions.35 Nevertheless, our own unpublished
observations suggest that CD34 highlights a broader perivascular
cell population, and that Gli1+ adventitial cells represent only a
subpopulation within this more largely distributed CD34+
perivasculature.
In summary, perivascular cell preparations from AT are an
appealing autologous cellular therapy for bone repair. CD146+
pericytes and CD34+ adventitial cells share fundamental attributes
including progenitor cell identity, multipotentiality, and immunor-
egulatory features. Yet, functional differences exist in paracrine-
induced osteogenesis, vasculogenesis, and paracrine-induced
bone repair between perivascular progenitor cell populations.
For the future, detailed studies that improve upon our correlation
between organ and vessel of origin, distinguishing cell surface
markers, and functional outcome post-transplantation are
required to better harness the regenerative properties of the
perivasculature.
METHODS
Isolation of human CD146+ pericytes and CD34+ adventitial
cells
Human lipoaspirate was obtained from healthy adult donors under
institutional IRB approval with a waiver of informed consent, and was
stored no > 72 h at 4 °C before processing. No patient identiﬁers were
obtained. The SVF was obtained by collagenase digestion, according to
previously published methods.19 In brief, lipoaspirate was washed with an
equal volume of phosphate-buffered saline (PBS). The washed lipoaspirate
was digested with 1 mg/ml type II collagenase in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 3.5% bovine serum albumin (Sigma-
Aldrich, St. Louis, MO) at 37 °C for 70min under agitation. Adipose cells
were isolated and removed by centrifugation. The cell pellet was
resuspended and incubated in red cell lysis buffer (155mM NH4Cl, 10mM
KHCO3, and 0.1 mM ethylenediaminetetraacetic acid (EDTA) at room
temperature for 10min. After centrifugation, the cells were resuspended
in PBS and ﬁltered at 70 μm. The resulting SVF was further processed for
FACS. Cells were incubated with anti-CD34− allophycocyanin (1:100; BD
Pharmingen, San Diego, CA), anti-CD146-ﬂuorescein isothiocyanate
(1:100; Bio-Rad, Hercules, CA), anti-CD45− allophycocyanin-cyanin
7 (1:100; BD Pharmingen) and anti-CD31− allophycocyanin–cyanin
7 (1:100, Bio Legend, San Diego, CA) for 20min on ice. See Supplementary
Table 1 for a list of antibodies used. In this manner,
pericytes (CD146+CD34−CD45−CD31−) and adventitial cells
(CD34+CD146−CD45−CD31−) were isolated. Data were collected on a
MoFlo XDP (Beckman Coulter, Indiana, USA) and analyzed using Summit
Software. For in vitro studies, cells were expanded at 37 °C in a humidiﬁed
atmosphere containing 95% air and 5% CO2. Unless otherwise stated, cells
were cultured in DMEM containing 20% fetal bovine serum (FBS), and 1%
penicillin/streptomycin.
Mouse calvarial defects
All animal studies were performed with institutional ACUC approval within
Johns Hopkins University, complying with all relevant ethical regulations.
Non-healing, critical-sized (4 mm diameter) calvarial defects were per-
formed in the parietal bone of 18-week-old male NOD/SCID mice as
previously described (001303, Jackson Labs, CA, USA).36 After anesthesia
with isoﬂurane and oxygen mixture, subcutaneous injection of buprenor-
phine (0.05 mg/kg) was used for pain relief. The hair over the cranial bone
was shaved and the skin was aseptically prepared using poviodine/
betadine scrub. A sagittal skin incision was made and the pericranium was
removed from the parietal bone. A 4mm full-thickness defect was made
using a high-speed dental surgical drilling unit with a trephine, without
injury to the adjacent sutures or underlying dura mater. After ﬂushing the
defect site with normal saline, a custom fabricated, previously validated,
hydroxyapatite-coated 85/15 PLGA scaffold was placed (PLGA inherent
viscosity 0.55–0.75 dL/g). In brief, for scaffold fabrication, PLGA/chloroform
solutions were mixed with 200–300m diameter sucrose to obtain 92%
porosity (volume fraction), and compressed into thin sheets in a Teﬂon
mold. A freeze-drying overnight, scaffolds were immersed in three changes
of ddH20 to dissolve the sucrose, and gently removed from the Teﬂon
plate with a ﬁne-tip spatula. Next, apatite-coating solution was prepared
and applied to PLGA scaffolds as described in previous studies.37 Scaffolds
were subjected to glow discharge argon plasma etching, followed by serial
incubation in simulated body ﬂuids.37 The apatite-coated scaffolds were
washed with sterile ddH20 to remove excess ions and lyophilized before
further studies. See ref. 20 for further a description of scaffold fabrication.
Animals were divided into ﬁve treatment groups: (1) No scaffold group
(an empty defect), (2) Scaffold alone group (PBS without cells placed on
scaffold), (3) Pericyte group (2.5×10^5 CD146+CD34−CD45−CD31−per-
icytes in PBS were incubated with the scaffold for 3 h and then placed in
the defect site), (4) Adventitial group (2.5×105
CD34+CD146−CD45−CD31−adventitial cells were incubated with the
scaffold for 3 h and then placed in the defect site), and (5) Pericyte+
Adventitial group: (1.25×105 adventitial cells and 1.25×105 pericytes were
incubated with the scaffold for 3 h and then placed in the defect site). Total
cell numbers were based on prior publications.19 See Supplementary
Figure 1 and Supplementary Table 2 for treatment group allocation. Finally,
the skin was sutured closed. Defects were harvested at 8 weeks after
surgery for analysis.
Validation of scaffold seeding
Pericytes or adventitial cells alone (2.5×105 cells, n= 3 per group) were
incubated with scaffold using the above protocol for 3 h and then
visualized using the Live/Dead kit according to the manufacturer’s
instructions (Thermo ﬁsher Scientiﬁc, MA, USA). The cellular distribution
as well as Live/Dead staining within the scaffold was visualized in n= 6
random high power ﬁelds per scaffold by confocal microscopy with z-stack
image acquisition (Zeiss LSM 800, Germany).
MicroCT imaging and analysis
Calvaria were dissected free and evaluated using a SkyScan1175 (Bruker,
MA, USA) high-resolution microCT imaging system. Each calvaria was
scanned separately at 65 kV and 153 µA with a 1.0-mm aluminum ﬁlter to
obtain a 10 µm voxel size. Scan slices were acquired in the coronal plane
by placing the bone parallel to the z-axis of the scanner. NRecon (Bruker)
was used to reconstruct images using the following settings: smoothing 1,
ring artifact reduction of 5% and beam hardening correction of 20%, and
quantitative analysis was performed using CTAn (Bruker) in accordance
with the recommendations of the American Society for Bone and Mineral
Research.38 Volumes of interest were disc shaped to encompass the
circular bone defect and were 4.3 mm in diameter. All analysis was
performed in a blinded fashion.
Histology and histomorphometry
Eight weeks postoperatively, calvaria of mice were harvested, ﬁxed in 4%
paraformaldehyde for 24 h, decalciﬁed with 12.5% EDTA (pH7.0) for
30 days, and embedded in parafﬁn. Calvarial defect sections were obtained
in a coronal plane at 10 um thickness. Immunohistochemistry for Human
Nuclear Antigen was performed using the primary antibody against human
nuclei (MAB1281, Millipore, CA, USA), a biotinylated secondary antibody
(BA-9200, Vector Labs, CA, USA), and the chromogenic DAB Peroxidase
Substrate Kit (SK-4100, Vector Labs, CA, USA) according to the
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manufacturer instructions. Sections were stained with H&E or Masson’s
Trichrome (TH15, Sigma-Aldrich, MO, USA). Random 10 × and 20 × images
of H&E-stained slides (N= 6 images per sample) were obtained for semi-
quantitative histomorphometric analysis, including the following para-
meters: (1) bone area (mean area measurement of bone expressed in
mm2), (2) vessel density (number of vessels per mm2 tissue area), (3) vessel
area (total vascular area per tissue area). All analysis was performed in a
blinded fashion.
For PKH26 (PKH26GL, Sigma-Aldrich, MO, USA) visualization in vivo, cells
were labeled with PKH26 ﬂuorescent dye according to the manufacturer’s
instructions, followed by engraftment in the calvarial defect model. Three
days postoperatively, calvaria of mice were harvested, ﬁxed in 4%
paraformaldehyde for 24 h, decalciﬁed with 12.5% EDTA (pH7.0) for
30 days, and embedded in OCT. Calvarial defect sections were obtained in
a coronal plane at 15 µm thickness. In vivo cell engraftment/persistence
was examined by ﬂuorescence microscopy (Leica DM6, Leica Microsys-
tems, Wetzlar, Germany). TUNEL staining (C10617, Invitrogen, MA, USA)
was conducted within the sections according to the manufacturer’s
instructions. For Ki67 immunoﬂuorescence, sections were washed in 1×
PBS, blocked in 5% normal goat serum (S-10000, Vector Labs, CA, USA), and
incubated with primary antibodies speciﬁc for Ki67 (1:200, ab16667,
Abcam, Cambridge, MA) at 4 ℃ overnight. Then sections were incubated
with Alexa Fluor® 647-conjugated Secondary antibodies (1:200, ab150083,
Abcam, Cambridge, MA), and mounted with mounting medium containing
DAPI (H-1500, Vector Labs, CA, USA).
Cord formation assays
CD146+ pericytes and CD34+ adventitial cells derived from the same
patient and of equal passage number were labeled with PKH26 red
ﬂuorescent dye before use (PKH26GL, Sigma-Aldrich, MO, USA). Growth
factor reduced Matrigel (BD Biosciences, CA, USA) was plated in 96-well
culture plates and incubated at 37 °C to polymerize for 30min.
For co-culture assays, HUVECs (C2517A, Lonza, USA) (15,000 cells/well)
were seeded at the same time with either CD146+ pericytes or CD34+
adventitial cells (500 cells/well) on the polymerized matrigel. Cells were
cultured with EGM2: DMEM (1:1) for 1 h. Cord formation was observed by
microscopy by analysis of random × 10 ﬁelds (IX71, Olympus, Japan),
including cord length per FV, branchpoints, per PV, and mesh numbers per
FV. N= 3 wells and three images per group.
To monitor cell attachment to already formed vascular cords, HUVECs
(15,000 cells/well) were seeded on the polymerized matrigel for 3 h for
cord formation. Then PKH26-labeled pericytes or adventitial cells (3500
cells/well) were added to wells containing HUVEC cords and cultured for
another 1 and 4 h. The attachment of CD146+ pericytes and CD34+
adventitial cells on HUVEC-generated cords was observed by analysis of
random 10x ﬁelds. Attachment was deﬁned by two methods, including (1)
cells attached and spread on the HUVEC cords, or (2) cells attached to
branchpoints. N= 3 wells and three images per group.
Secretome analysis
CD146+ pericytes and CD34+ adventitial cells derived from the same
patient and of equal passage number were plated at 1.5×105/ml density in
six-well plate cell culture dishes (2 mL per well). Upon subconﬂuency,
standard growth medium was substituted for serum free DMEM (1.5 mL
per well). Supernatant was collected 24 h later, centrifuged at 500 g for
5 min and then stored at − 20℃. Secretome analysis was performed with
the Human Angiogenesis Array kit (ARY007) according to the manufac-
turer’s instructions (R&D system, Minneapolis, MN, USA). Visualization was
performed with the ChemiDoc Touch Imaging System (Bio-Rad, CA, USA).
The average signal (pixel density) of the pair of duplicate spots
representing each angiogenesis-related protein was normalized on an
averaged background signal from negative control spots. Corresponding
signals were compared to determine the relative difference in
angiogenesis-related proteins secreted by CD146+ pericytes and CD34+
adventitial cells.
Osteogenic differentiation assays
CD146+ pericytes and CD34+ adventitial cells derived from the same
patient sample were cultured in osteogenic differentiation medium,
composed of DMEM, 10% FBS, 1% penicillin/streptomycin with 100 nM
Dexamethasone, 10 mM β-glycerophosphate, and 50 μM ascorbic acid
(Sigma-Aldrich). Medium was changed every 3 days. For non-contact co-
culture, 24-well Transwell plates (Millipore, Darmstadt, Germany) with
0.4 μm pore ﬁlters were used. A total of 1 × 105/ well of either CD146+
pericytes or CD34+ adventitial cells were seeded in 24-well plates on the
lower chamber. The opposing cell type was seeded on the upper transwell
plates (1 × 104/well).
To detect mineralization, cultures were stained with Alizarin Red S at
14 days of differentiation (Sigma-Aldrich, USA). Finally, 0.1 N sodium
hydroxide was used to dissolve the calcium precipitate and the solving
liquid was quantiﬁed by absorbance at 548 nm (Epoch spectrophotometer,
Biotek, VT, USA). N= 3 wells per condition.
To analyze osteogenic gene and angiogenic-related gene expression,
TRIzol reagent (Life technology, CA, USA) was used for total RNA isolation
at 7 days of differentiation. RNA was reverse transcribed into cDNA by
iScript cDNA Synthesis Kit (Bio-Rad, CA, USA) according to the
manufacturer’s instructions. RT-PCR was performed using SYBR Green
PCR Master Mix (Thermo ﬁsher Scientiﬁc, MA, USA). Primer information
presented in Supplementary Table 3.
Statistical analysis
Results are expressed as the mean ± SD. Statistical analysis was performed
using either a Student’s t test for a two sample comparison, or analysis of
variance followed by a post hoc Student’s t test (Graphpad Software 6.0).
*P < 0.05 and **P < 0.01 were considered signiﬁcant.
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